Press release
Treatment Resistant Depression Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Explore our latest breakthroughs in Treatment Resistant Depression Research. Learn more about our innovative pipeline today! @ Treatment Resistant Depression Pipeline Outlook [https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Treatment Resistant Depression Pipeline Report
* In November 2024:- COMPASS Pathways- A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression. This is a phase III, international, multi-centre, randomised, parallel group, fixed repeat dose, double-blind, controlled study. The study population will include participants aged greater than or equal to 18 years with TRD.
* In October 2024: Mapreg- Double-blind,Controlled,Randomized Phase 2 Study of Efficacy,Safety,Pharmacokinetics& Pharmacodynamics of Daily Oral Administration of MAP4343 During 6 Weeks in Antidepressant Non-responders Patients Experiencing a Major Depressive Episode. This is a phase II, versus placebo, multicentre, double blind, randomized, parallel study in male or female patients with drug resistant depression.
* DelveInsight's Treatment Resistant Depression pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Treatment Resistant Depression treatment.
* The leading Treatment Resistant Depression Companies such as Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Navitor Pharmaceuticals, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, ATAI Life Sciences, and others.
* Promising Treatment Resistant Depression Therapies such as GH001, VLS-01, Psilocybin, BPL-003, NV-5138, Ebselen, OSU6162 , and others.
Stay informed about the cutting-edge advancements in Treatment Resistant Depression treatments. Download for updates and be a part of the revolution in care @ Treatment Resistant Depression Clinical Trials Assessment [https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Treatment Resistant Depression Emerging Drugs Profile
* Psilocybin: COMPASS Pathways
Psilocybin therapy is an approach being investigated for the treatment of mental health challenges. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support. Psilocybin is an active ingredient in some species of mushrooms, often referred to as 'magic mushrooms'. The company has developed a synthesised formulation of psilocybin, COMP 360, and is investigating the effectiveness of psilocybin therapy, initially in treatment-resistant depression.
* AXS-05: Axsome Therapeutics
AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of central nervous system (CNS) conditions. AXS-05 consists of a proprietary formulation and dose of dextromethorphan (DM) and bupropion. The dextromethorphan component of AXS-05 is an antagonist of the NMDA receptor, an ionotropic glutamate receptor, and a sigma-1 receptor agonist. These actions modulate glutamatergic neurotransmission. The bupropion component of AXS-05 serves primarily to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor
Learn more about Treatment Resistant Depression Drugs opportunities in our groundbreaking Myelofibrosis Research and development projects @ Treatment Resistant Depression Unmet Needs [https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Treatment Resistant Depression Companies
Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Navitor Pharmaceuticals, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, ATAI Life Sciences, and others.
Treatment Resistant Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
* Molecule Type
Treatment Resistant Depression Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Discover the latest advancements in Treatment Resistant Depression treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Treatment Resistant Depression Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Treatment Resistant Depression Pipeline Report
* Coverage- Global
* Treatment Resistant Depression Companies- Axsome Therapeutics, COMPASS Pathways, Merck Sharp & Dohme Corp., Navitor Pharmaceuticals, Inc., Taisho Pharmaceutical Co., Ltd., GH Research Limited, Novartis Pharmaceuticals, Reckitt Benckiser LLC, Relmada Therapeutics, Inc., SAGE Therapeutics, Navitor Pharmaceuticals, Sumitomo Dainippon Pharma, Alkermes, AbbVie, Janssen Pharmaceuticals, Celon Pharma, ACADIA Pharmaceuticals, Pherin Pharmaceuticals, ATAI Life Sciences, and others.
* Treatment Resistant Depression Therapies- GH001, VLS-01, Psilocybin, BPL-003, NV-5138, Ebselen, OSU6162, and others.
* Treatment Resistant Depression Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Treatment Resistant Depression Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Treatment Resistant Depression Pipeline on our website @ Treatment Resistant Depression Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Treatment Resistant Depression: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Preregistration)
* AXS-05: Axsome Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Psilocybin: COMPASS Pathways
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* SEP-378614: Sumitomo Dainippon Pharma
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Treatment Resistant Depression Key Companies
* Treatment Resistant Depression Key Products
* Treatment Resistant Depression- Unmet Needs
* Treatment Resistant Depression- Market Drivers and Barriers
* Treatment Resistant Depression- Future Perspectives and Conclusion
* Treatment Resistant Depression Analyst Views
* Treatment Resistant Depression Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=treatment-resistant-depression-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Treatment Resistant Depression Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers here
News-ID: 3718848 • Views: …
More Releases from ABNewswire
The Essential Guide to U-Bolts - Specifications and Industry Applications
In the world of heavy-duty trucks, where every component must withstand immense stress, one humble part plays a disproportionately critical role: the U-bolt [https://www.jqtruckparts.com/u-bolt/]. Though simple in design, this fastener is essential for vehicle safety, performance, and stability.
Image: https://www.jqtruckparts.com/uploads/U%E5%9E%8B3.jpg
What is a U-Bolt? A U-bolt is a U-shaped mounting bolt made from high-strength steel rod,with threaded ends fitted with nuts and washers. Its primary function is to securely clamp the axle…
What is the difference between a hinge and a door hinge?
Hinges are essential components in the world of furniture hardware, being the key connections that enable various structures to open and close smoothly. Although the terms "hinge" and "Door Hinge [https://www.monsoonhardware.com/door-hinge/]" are often used interchangeably, they refer to different applications with different characteristics that meet specific needs. Understanding these differences is essential for anyone involved in construction, renovation or furniture design.
A hinge is essentially a mechanical device that connects two…
CNC Electric Strengthens Partnership with BI GROUP in Kazakhstan
CNC Electric Strengthens Partnership with BI GROUP in Kazakhstan
CNC Electric is proud to announce a significant milestone in our collaboration with BI GROUP, one of Kazakhstan's leading real estate developers. By joining BI GROUP's approved vendor roster, CNC Electric is now positioned to support new large-scale projects and expand our presence across the region.
Prior to This Collaboration
Key BI GROUP specialists visited our China manufacturing facility, where they firsthand verified CNC…
How to convert process pipelines into instrument pipelines? Hikelok provides wit …
First, let's understand what a process pipeline is? What is an instrument pipeline.
Process pipeline: a pipeline used for conveying, distributing, mixing, separating, discharging, metering, controlling, and buffering fluid flow. Simply put, it refers to the main pipelines of oil, petrochemical, chemical and other plants, and the process pipelines are designed by process designers.
Instrument pipeline: Signal piping in contact with process fluids and temperature pressure conditions. Usually used for measuring temperature,…
More Releases for Treatment
Trigeminal Neuralgia Treatment Market Size, Trigeminal Neuralgia Treatment Marke …
Trigeminal Neuralgia Treatment Market Dynamics are clarified by an in-depth review of facts on current and emerging trends. To understand a resource, the paper uses Porter's five forces to examine the importance of numerous qualities such as understanding of suppliers and customers, dangers provided by various agents, competitive strength, and promising new businesses. precious. Furthermore, the study covers numerous firms' Trigeminal Neuralgia Treatment research data, benefit, gross margin, worldwide market…
Medical Tourism Market Report by Treatment Type (Dental Treatment, Cosmetic Trea …
The global medical tourism market accounted for $104.68 billion in 2019, and is projected to reach $273.72 billion by 2027, registering a CAGR of 12.8% from 2019 to 2027 in terms of value.
View Full Report: https://reports.valuates.com/market-reports/ALLI-Auto-0P310/medical-tourism
In terms of volume, the global medical tourism market accounted for 23,042.90 thousand patients in 2019, and is projected to reach 70,358.61 thousand patients by 2027, registering a CAGR of 15.0% from 2019 to…
Stretch Marks Treatment Market by Treatment & Forecast - 2025
Global Stretch Marks Treatment Market: Snapshot
In order to expand their outreach and add to their product portfolio, keen players in the global stretch marks treatment market are taking the inorganic route of acquisitions. They are also pouring money into development of new and better products.
Rising instances of obesity causing stretch marks is serving to catalyze growth in the market. In addition, growing aesthetic consciousness among people, especially among pregnant women,…
Stretch Marks Treatment Market by Treatment & Forecast - 2025
Global Stretch Marks Treatment Market: Snapshot
In order to expand their outreach and add to their product portfolio, keen players in the global stretch marks treatment market are taking the inorganic route of acquisitions. They are also pouring money into development of new and better products.
Rising instances of obesity causing stretch marks is serving to catalyze growth in the market. In addition, growing aesthetic consciousness among people, especially among pregnant women,…
Medical Tourism Market by Treatment Type (Dental Treatment, Cosmetic Treatment, …
Medical Tourism Market Overview:
The global medical tourism market was valued at $53,768 million in 2017, and is estimated to reach at $143,461 million by 2025, registering a CAGR of 12.9% from 2018 to 2025.
Organized travel across international borders to avail medical treatment of some form, which may or may not be available in the travelers home country is defined as medical tourism. Medical tourists travel abroad for the maintenance, enhancement,…
Substance Use Disorder Treatment Market By Type (Alcohol abuse treatment, Nicoti …
According to World Health Organization (WHO), the leading cause of disability around the world is not a physical disease, but a serious mood disorder known as depression. Around 350 million people suffer from depression worldwide, and that only about 50% of these individuals will ever receive treatment. According to Anxiety and Depression Association of America, in the U.S., over 15 million adults experience an episode of clinical depression in any…
